$1.22
Live
1.59%
Downside
Day's Volatility :8.7%
Upside
7.22%
72.68%
Downside
52 Weeks Volatility :88.62%
Upside
58.36%
Period | Fibrogen Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 18.27% | 6.5% | 0.0% |
6 Months | 31.42% | 7.1% | 0.0% |
1 Year | -34.22% | 9.8% | 0.0% |
3 Years | -90.6% | 14.2% | -20.2% |
Market Capitalization | 122.4M |
Book Value | - $2.29 |
Earnings Per Share (EPS) | -2.44 |
PEG Ratio | 0.0 |
Wall Street Target Price | 1.75 |
Profit Margin | -143.56% |
Operating Margin TTM | -55.57% |
Return On Assets TTM | -34.39% |
Return On Equity TTM | -1015.79% |
Revenue TTM | 167.5M |
Revenue Per Share TTM | 1.7 |
Quarterly Revenue Growth YOY | 54.6% |
Gross Profit TTM | -159.2M |
EBITDA | -241.0M |
Diluted Eps TTM | -2.44 |
Quarterly Earnings Growth YOY | 0.54 |
EPS Estimate Current Year | -1.31 |
EPS Estimate Next Year | -0.57 |
EPS Estimate Current Quarter | -0.42 |
EPS Estimate Next Quarter | -0.39 |
What analysts predicted
Upside of 43.44%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 213.0M | ↑ 69.46% |
Net Income | -86.4M | ↓ 31.52% |
Net Profit Margin | -40.58% | ↑ 59.85% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 256.6M | ↑ 20.48% |
Net Income | -77.0M | ↓ 10.93% |
Net Profit Margin | -30.0% | ↑ 10.58% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 176.3M | ↓ 31.28% |
Net Income | -189.3M | ↑ 145.93% |
Net Profit Margin | -107.36% | ↓ 77.36% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 235.3M | ↑ 33.46% |
Net Income | -291.0M | ↑ 53.75% |
Net Profit Margin | -123.68% | ↓ 16.32% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 140.7M | ↓ 40.19% |
Net Income | -295.2M | ↑ 1.44% |
Net Profit Margin | -209.78% | ↓ 86.1% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 147.8M | ↑ 4.99% |
Net Income | -284.2M | ↓ 3.72% |
Net Profit Margin | -192.37% | ↑ 17.41% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 34.4M | ↑ 118.41% |
Net Income | -66.5M | ↓ 27.81% |
Net Profit Margin | -193.37% | ↑ 391.68% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 36.2M | ↑ 5.22% |
Net Income | -77.5M | ↑ 16.62% |
Net Profit Margin | -214.32% | ↓ 20.95% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 44.3M | ↑ 22.56% |
Net Income | -87.7M | ↑ 13.13% |
Net Profit Margin | -197.84% | ↑ 16.48% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 40.1M | ↓ 9.44% |
Net Income | -63.6M | ↓ 27.45% |
Net Profit Margin | -158.51% | ↑ 39.33% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 27.1M | ↓ 32.38% |
Net Income | -56.2M | ↓ 11.61% |
Net Profit Margin | -207.21% | ↓ 48.7% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 55.9M | ↑ 105.99% |
Net Income | -32.9M | ↓ 41.43% |
Net Profit Margin | -58.91% | ↑ 148.3% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 880.6M | ↓ 2.01% |
Total Liabilities | 352.1M | ↑ 11.36% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 857.4M | ↓ 2.63% |
Total Liabilities | 322.0M | ↓ 8.56% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 826.8M | ↓ 3.56% |
Total Liabilities | 385.4M | ↑ 19.69% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 773.8M | ↓ 6.41% |
Total Liabilities | 544.7M | ↑ 41.34% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 610.1M | ↓ 21.16% |
Total Liabilities | 611.6M | ↑ 12.27% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 423.5M | ↓ 30.58% |
Total Liabilities | 585.7M | ↓ 4.23% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 610.1M | ↑ 0.21% |
Total Liabilities | 611.6M | ↑ 8.71% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 538.5M | ↓ 11.73% |
Total Liabilities | 567.4M | ↓ 7.22% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 515.1M | ↓ 4.35% |
Total Liabilities | 575.4M | ↑ 1.41% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 460.4M | ↓ 10.62% |
Total Liabilities | 575.6M | ↑ 0.03% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 423.5M | ↓ 8.01% |
Total Liabilities | 585.7M | ↑ 1.75% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 365.9M | ↓ 13.61% |
Total Liabilities | 552.0M | ↓ 5.75% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -76.1M | ↑ 14.48% |
Investing Cash Flow | -522.1M | ↓ 847.32% |
Financing Cash Flow | 13.9M | ↓ 97.21% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -78.7M | ↑ 3.36% |
Investing Cash Flow | 120.0M | ↓ 122.99% |
Financing Cash Flow | -4.3M | ↓ 130.99% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 81.6M | ↓ 203.68% |
Investing Cash Flow | 452.5M | ↑ 277.02% |
Financing Cash Flow | 13.3M | ↓ 410.3% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -82.2M | ↓ 200.77% |
Investing Cash Flow | -427.0M | ↓ 194.36% |
Financing Cash Flow | -563.0K | ↓ 104.22% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -145.9M | ↑ 77.46% |
Investing Cash Flow | 89.1M | ↓ 120.87% |
Financing Cash Flow | 46.8M | ↓ 8408.35% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -52.5M | ↑ 1.22% |
Investing Cash Flow | 1.1M | ↓ 97.56% |
Financing Cash Flow | 48.7M | ↓ 4557.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -101.6M | ↑ 93.46% |
Investing Cash Flow | 103.5M | ↑ 9367.7% |
Financing Cash Flow | 31.5M | ↓ 35.31% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -110.6M | ↑ 8.84% |
Investing Cash Flow | -14.3M | ↓ 113.8% |
Financing Cash Flow | 91.5M | ↑ 190.72% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -84.5M | ↓ 23.54% |
Investing Cash Flow | 54.2M | ↓ 479.54% |
Financing Cash Flow | -22.0K | ↓ 100.02% |
Sell
Neutral
Buy
Fibrogen Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Fibrogen Inc | 16.59% | 31.42% | -34.22% | -90.6% | -97.44% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Fibrogen Inc | NA | NA | 0.0 | -1.31 | -10.16 | -0.34 | NA | -2.29 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Fibrogen Inc | Sell | $122.4M | -97.44% | NA | -143.56% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Fibrogen Inc
Revenue is up for the last 2 quarters, 27.13M → 55.90M (in $), with an average increase of 51.5% per quarter
Netprofit is up for the last 4 quarters, -87.68M → -32.93M (in $), with an average increase of 40.6% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 95.8%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 277.1%
PRIMECAP Management Company
Armistice Capital, LLC
BlackRock Inc
Vanguard Group Inc
Acadian Asset Management LLC
Jacobs Levy Equity Management, Inc.
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
Organization | Fibrogen Inc |
Employees | 486 |
CEO | Mr. Thane Wettig |
Industry | Health Technology |
A Spac I Acquisition Corp
$1.22
-0.81%
Keyarch Acquisition Corp
$1.22
-0.81%
Connexa Sports Technologies Inc
$1.22
-0.81%
Us Value Etf
$1.22
-0.81%
First Wave Biopharma Inc
$1.22
-0.81%
Global X Msci Next Emerging
$1.22
-0.81%
Fat Projects Acquisition Corp
$1.22
-0.81%
Capital Link Global Fintech
$1.22
-0.81%
Applied Uv Inc
$1.22
-0.81%